Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 10413591
    Abstract: Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 17, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: S. Ananth Karumanchi, Vikas P. Sukhatme
  • Patent number: 10364295
    Abstract: Purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences are provided.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 30, 2019
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Patent number: 10365282
    Abstract: A method for assessing sarcoma metastasis comprising obtaining a biological sample of the subject, detecting a level of a N-terminal segment of moesin in the biological sample, wherein the level of the N-terminal segment of moesin detected in the biological sample of the subject is indicative of the subject developing or with an increased probability of developing metastasis of sarcoma. The present application also provides a biomarker and a kit for assessing metastasis of sarcoma, and uses of such biomarker. The present application also provides a method of treating sarcoma metastasis.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 30, 2019
    Assignee: SHANGHAI KEXIN BIOTECH CO., LTD.
    Inventors: Yue Zhang, Jun Bao
  • Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10351852
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: July 16, 2019
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: James McSwiggen, Leonid Beigelman, Chandra Vargeese
  • Patent number: 10344283
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 9, 2019
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • Patent number: 10316099
    Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 11, 2019
    Assignee: D-GEN LIMITED
    Inventors: John Collinge, Andrew J Nicoll
  • Patent number: 10307487
    Abstract: Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: June 4, 2019
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital
    Inventors: Ulrich H. von Andrian, Aude Thiriot, Omid Farokhzad, Jinjun Shi
  • Patent number: 10301379
    Abstract: The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 28, 2019
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Jehangir Wadia, Gabriel Pascual, Robert Anthony Williamson, Katarina Radosevic, Jaap Goudsmit
  • Patent number: 10301362
    Abstract: A method and composition for eliciting an immune response to group A streptococcal bacteria in a mammal is provided, which includes administering to the mammal an M protein fragment, variant or derivative thereof and a SpyCEP protein or peptide fragment, or an antibody to the SpyCEP protein or fragment to facilitate restoring or enhancing neutrophil activity. Also provided is an immunodominant peptide fragment of SpyCEP.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: May 28, 2019
    Assignee: Griffith University
    Inventors: Manisha Pandey, Michael Batzloff, Michael Good
  • Patent number: 10293023
    Abstract: Provided here are methods of modulating vascular permeability by changing the mechanical properties of extracellular matrices (ECM) and methods of treatment of diseases, conditions and symptoms related to vascular permeability such as pulmonary edema and acute respiratory distress syndrome (ARDS). The modulation can be increasing or decreasing vascular permeability. Vascular leakage can be normalized by increasing or decreasing ECM stiffness depending on the baseline mechanical properties of the tissue or organ. Vascular permeability is altered by changing the mechanical properties of ECM by administering a lysyl oxidase modulating (LOX) agent.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 21, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Akiko Mammoto
  • Patent number: 10294300
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 21, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
  • Patent number: 10287358
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 14, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10286076
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: May 14, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10279022
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 7, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10266600
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: April 23, 2019
    Assignee: APOGENIX AG
    Inventors: Harald Fricke, Christian Gieffers, Jaromir Sykora
  • Patent number: 10259865
    Abstract: The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 16, 2019
    Assignee: ADMA Biologics, Inc.
    Inventors: James Mond, Adam S. Grossman
  • Patent number: 10259863
    Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: April 16, 2019
    Assignee: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Feng Wang, Yong Zhang, Peter G. Schultz
  • Patent number: 10227404
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 12, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 10227397
    Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 12, 2019
    Assignee: INFLARX GMBH
    Inventors: Renfeng Guo, Niels Christoph Riedemann
  • Patent number: 10208349
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 19, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Sairfull Watt
  • Patent number: 10208124
    Abstract: The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 19, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), MABLIFE
    Inventors: Philippe Le Bouteiller, Armand Bensussan
  • Patent number: 10188647
    Abstract: A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: January 29, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Young Mi Oh, Kyung Ah Kim
  • Patent number: 10174106
    Abstract: The present invention relates to a neutralizing antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralizes the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralizing antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventor: Patricia Forgez
  • Patent number: 10172858
    Abstract: The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 8, 2019
    Assignee: INTELLIKINE LLC
    Inventors: Yi Liu, Pingda Ren, Katayoun Jessen, Xin Guo, Christian Rommel
  • Patent number: 10167474
    Abstract: Provided herein are fluoropyrimidine-modified RNA aptamers capable of binding CCR5. The compositions and methods provided herein are, inter alia, useful for the delivery of antiviral drugs (e.g., siRNAs) and preventing HIV entry into a target cell.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 1, 2019
    Assignees: City of Hope, The Scripps Research Institute
    Inventors: John Rossi, Jiehua Zhou, Marc Weinberg, Kevin Morris
  • Patent number: 10159679
    Abstract: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterized by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: December 25, 2018
    Inventors: Kevin J. Barnham, Paul S. Donnelly, Anthony R. White
  • Patent number: 10161930
    Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: December 25, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Charlotte Beau-Larvor, Liliane Goetsch
  • Patent number: 10151754
    Abstract: The present invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody, such as MIL-38. The invention includes kits for detection of prostate cancer in a body fluid sample, comprising an anti-glypican-1 antibody and glypican-1 standards.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 11, 2018
    Assignee: Minomic International Ltd.
    Inventors: Bradley Walsh, Douglas Campbell, Irene Justiniano Fuenmayor, Aline Nocon, Julie Soon, Quach Truong, Sandra Wissmueller, Pamela Russell
  • Patent number: 10131957
    Abstract: The present invention provides breast cancer markers based on RECQL mutations, and related methods, uses, agents, and kits. The invention includes methods for determining the susceptibility of a subject to developing breast cancer, and methods for detecting, diagnosing, treating, and predicting responses to treatment for breast cancer.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 20, 2018
    Assignee: Women's College Hospital
    Inventor: Mohammad R. Akbari
  • Patent number: 10125196
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: November 13, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Michael Koslowski, Özlem Türeci
  • Patent number: 10105424
    Abstract: The present invention relates to nucleotide sequences encoding Cooperia antigens, as well as to recombinant DNA molecules containing such nucleotide sequences and host cells expressing these nucleotide sequences. The invention further relates to Cooperia proteins, to methods for the production of the proteins, nucleotide sequences, recombinant DNA molecules and hosts. Furthermore, the invention relates to vaccines which induce protective immunity against infection by parasitic nematodes such as species of the genus Cooperia and to methods for preparing such a vaccine.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 23, 2018
    Assignee: Universiteit Gent
    Inventors: Peter Geldhof, Jimmy Borloo, Edwin Claerebout, Jozef Vercruysse
  • Patent number: 10093737
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: October 9, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventor: Xingxing Zang
  • Patent number: 10076571
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 18, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gary Swergold
  • Patent number: 10077314
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 18, 2018
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10072087
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 11, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10071131
    Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 11, 2018
    Assignee: BioIncept, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 10059946
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 28, 2018
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Frédéric Jaisser, Nicolette Farman
  • Patent number: 10053495
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: August 21, 2018
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Christopher C. Broder, Katharine N. Bossart
  • Patent number: 10053476
    Abstract: The invention relates to phosphohistidine analogs. The invention also relates to antibodies that specifically bind to the analogs and methods of generating said antibodies. In one embodiment of the invention there is provided a phosphohistidine analog of Formula V: (V) wherein W is selected from H, CO2H or CONH2; and X is selected from CH or N.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: August 21, 2018
    Assignee: UNIVERSITY OF SHEFFIELD
    Inventors: Richard Jackson, Richmond Muimo, Matthew Lilley
  • Patent number: 10017822
    Abstract: Methods and compositions for identifying, diagnosing, and treating neuroblastoma are disclosed.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: July 10, 2018
    Assignee: The Children's Hospital of Philadelphia
    Inventors: John M. Maris, Yael P. Mosse, Erica L. Carpenter
  • Patent number: 10000558
    Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: June 19, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Stephanie Kwai Yee Ma, Man Tong, Xin-Yuan Guan
  • Patent number: 9988443
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky, Julia Neugebauer, Steffen Runz
  • Patent number: 9982011
    Abstract: The present invention discloses doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Len or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: May 29, 2018
    Assignee: Yafei (Shanghai) Biopharmaceutical Co., Ltd.
    Inventors: Cheng Liu, Yuan Liu
  • Patent number: 9982044
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 29, 2018
    Assignees: ZYMOGENETICS INC., MERCK SERONO S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Patent number: 9981027
    Abstract: The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 29, 2018
    Assignees: IDEMITSU KOSAN CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
    Inventors: Kazutoshi Sawada, Takeshi Matsui, Eiji Takita, Takashi Hamabata, Toshio Sato
  • Patent number: 9981020
    Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 29, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Kamel Khalili, Wenhui Hu
  • Patent number: 9968653
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: May 15, 2018
    Assignees: Regeneron Pharmaceuticals, Inc., University Health Network
    Inventors: Lisa Arleen Purcell Ngambo, Sarah J. Higgins, Kevin C. Kain
  • Patent number: 9969804
    Abstract: Antibodies (e.g., isolated antibodies) that specifically bind to human integrin ?8 and inhibit adhesion of latency associated peptide (LAP) to ?v?8 are provided. In some embodiments, the antibody cross-reacts with mouse integrin ?8. In some embodiments, the antibody blocks TGFJ3 activation. In some embodiments, the antibody antagonizes binding of LAP to ??8 with an IC50 below 5 nM.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: May 15, 2018
    Assignee: The Regents of the University of California
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson